TRMT1L

Across TCGA pan-cancer cohorts, TRMT1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRMT1L data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TRMT1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LIHC, and LUAD are the cancer types where TRMT1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.119	0.630	<.001	30	view →
LIHC	DFS	Median	All	0.046	0.553	<.001	18	view →
LUAD	OS	Median	III,IV	0.127	0.664	.001	12	view →
UCEC	DFS	Median	III,IV	1.000	0.542	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRMT1L–KIRC (OS)

Open the KIRC breakdown →